B. Will

First do no harm: extending the debate on the provision of preventive tamoxifen

M. Wolfson, J. Berthelot, W. Flanagan, 2001, British Journal of Cancer.

Cost of combined modality interventions for stage III non-small-cell lung cancer.

J. Berthelot, W. Evans, B. P. Will, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Diagnostic and therapeutic approaches to lung cancer in Canada and their costs.

M. Wolfson, J. Berthelot, W. Evans, 1995, British Journal of Cancer.

The cost of managing lung cancer in Canada.

M. Wolfson, J. Berthelot, W. Evans, 1995, Oncology.

The development of staging data for use in the microsimulation of lung cancer.

J. Gentleman, J. Berthelot, H. Berkel, 1992, Health reports.

A model for estimating the costs and burdens of breast cancer diagnosis and treatment in Canada.

J. Berthelot, C. Houle, E. Tomiak, 1993, Health reports.

The economics of lung cancer management in Canada.

M. Wolfson, J. Berthelot, W. Evans, 1996, Lung cancer.

Estimating the cost of lung cancer diagnosis and treatment in Canada: the POHEM model.

M. Wolfson, J. Berthelot, W. Evans, 1995, The Canadian journal of oncology.

Estimates of the lifetime costs of breast cancer treatment in Canada.

J. Berthelot, E. Tomiak, S. Verma, 2000, European journal of cancer.

Decision framework for chemotherapeutic interventions for metastatic non-small-cell lung cancer.

D. Coyle, J. Berthelot, W. Evans, 2000, Journal of the National Cancer Institute.

BREAST CANCER: BETTER CARE FOR LESS COST

J. Berthelot, W. Evans, B. P. Will, 2000, International Journal of Technology Assessment in Health Care.